Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance
Open Access
- 10 April 2006
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 5 (1) , 9
Abstract
Background: Impaired glucose tolerance (IGT) is associated with increased cardiovascular risk. The pathophysiological mechanisms linking post-challenge hyperglycemia to accelerated atherosclerosis, however remain to be elucidated. Methods: A prospective, open, randomised, cross-over study was performed to investigate the effect of 2 mg repaglinide on hyperglycemia and endothelial function during an oral glucose tolerance test (75 g glucose) in 12 subjects with diagnosed IGT. Blood samples for determination of plasma glucose were drawn fasting, 1 and 2 hours after glucose ingestion. Endothelial function was assessed by measuring flow-mediated dilatation (FMD) of the brachial artery with high-resolution ultrasound. Results: Administration of repaglinide resulted in a significant reduction of plasma glucose at 2 hours (172.8+/-48.4 vs. 138.3+/-41.2 mg/dl; p < 0.001). The flow-mediated dilatation (FMD) 2 hours after the glucose-load was significantly reduced in comparison to fasting in the control group (6.21+/-2.69 vs. 7.98+/-2.24 %; p = 0.028), whereas after theadministration of repaglinide the FMD was not significantly different to fasting values (7.24+/-2.57 vs. 8.18+/-2.93 %; p = n.s.). Linear and logistic regression analysis revealed that only the change of glucose was significantly correlated to the change of FMD observed (p < 0.001). Regression analysis after grouping for treatment and time confirmed the strong negative association of the changes of plasma glucose and FMD and indicate that the effect of repaglinide observed is based on the reduction glycemia. Conclusion: In subjects with IGT, the endothelial dysfunction observed after a glucose challenge is related to the extent of hyperglycemia. Reduction of hyperglycemia by repaglinide reduces endothelial dysfunction in a glucose dependent manner.Keywords
This publication has 15 references indexed in Scilit:
- Intense Cholesterol Lowering Therapy with a HMG-CoA Reductase Inhibitor does not Improve Nitric Oxide Dependent Endothelial Function in Type-2-DiabetesExperimental and Clinical Endocrinology & Diabetes, 2005
- Repaglinide Administration Improves Brachial Reactivity in Type 2 Diabetic PatientsDiabetes Care, 2005
- Reduction of Postprandial Hyperglycemia in Patients with Type 2 Diabetes Reduces NF-κB Activation in PBMCsHormone and Metabolic Research, 2004
- Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemiaAmerican Heart Journal, 2004
- The post‐prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspartDiabetic Medicine, 2004
- Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial FunctionCirculation, 2002
- Mechanisms Underlying Endothelial Dysfunction in Diabetes MellitusCirculation Research, 2001
- Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart DiseaseCirculation, 2000
- Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteriaThe Lancet, 1999
- Endothelial Dysfunction: Does It Matter? Is It Reversible?JACC, 1997